Related Experiment Video
Updated: Mar 8, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
Use of novel oral anticoagulant agents in venous thromboembolism
Shivanshu Madan1, Shenil Shah2, Patrick Dale3
1Department of Cardiovascular Medicine, University of North Carolina Hospitals, Chapel Hill, NC, USA.
Abstract:
New oral anticoagulants (NOAC) serve as alternatives for patients currently using warfarin for the prevention and treatment of venous thromboembolic (VTE) disease. This article provides a brief summary of the clinical use of these drugs as well as a review of the landmark clinical trials which evaluated described their safety and efficacy. As more data becomes available, a fundamental understanding of these medications will be vital to cardiovascular practitioners managing patients with VTE.
Insights
New oral anticoagulants (NOACs) offer alternatives to warfarin for preventing and treating venous thromboembolic (VTE) disease. This review covers their clinical use and trial data on safety and efficacy for cardiovascular practitioners.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Warfarin has been the standard for venous thromboembolic (VTE) disease treatment.
- Newer anticoagulants offer potential advantages in administration and monitoring.
Purpose of the Study:
- To review the clinical utility of new oral anticoagulants (NOACs).
- To summarize landmark trials evaluating NOAC safety and efficacy.
- To inform cardiovascular practitioners managing VTE patients.
Main Methods:
- Review of clinical trials on NOACs.
- Analysis of safety and efficacy data.
- Summary of clinical applications.
Main Results:
- NOACs demonstrate comparable or superior efficacy to warfarin in VTE prevention and treatment.
- NOACs generally show a favorable safety profile with reduced risk of major bleeding in certain contexts.
- Specific NOACs have different dosing and reversal strategies.
Conclusions:
- NOACs are effective alternatives to warfarin for VTE management.
- Understanding NOACs is crucial for optimal patient care in VTE.
- Ongoing research will further refine the role of NOACs in cardiovascular practice.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis IV: Nursing Management
Venous Thrombosis I: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

